In the randomized, double-blind, phase 3 study, experts explored treatment with neoadjuvant pembrolizumab (Keytruda) plus chemotherapy, followed by adjuvant pembrolizumab, in patients aged 18 years ...

This study is looking at an immunotherapy treatment called V940 (mRNA-4157) with pembrolizumab to treat melanoma.

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in ...

The following is a summary of "A phase 2 study of frontline pembrolizumab in follicular lymphoma," published in the October 2024 issue of Hematology by Ho et al. The tumor microenvironment (TME), ...

The imaging agent Gleolan is only approved for glioma surgery, so the current trial could lead to a new indication. In this ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The first patient with advanced gastric and gastroesophageal cancer has been dosed in a trial combining PT886 with ...

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab yields a significant improvement in overall survival ...

This emphasizes a critical issue as pembrolizumab is increasingly being used in early TNBC and could have long-term survivorship implications. Supported in part by The University of Texas MD Anderson ...

PT886 is currently being evaluated as monotherapy and in combination with pembrolizumab, or with chemotherapy, either alone or in combination with pembrolizumab. The multi-center Phase I/II ...